Stocks and Investing
Stocks and Investing
Thu, March 30, 2017
[ 09:45 AM ] - United States, WOPRAI
[ 09:45 AM ] - United States, WOPRAI
[ 09:45 AM ] - United States, WOPRAI
[ 09:45 AM ] - United States, WOPRAI
[ 09:45 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Wed, March 29, 2017
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Do Kim of BMO Capital, Upgraded "Vertex Pharmaceuticals Incorporated" (VRTX) to Buy on, Mar 29th, 2017.
Do has made no other calls on VRTX in the last 4 months.
There are 3 other peers that have a rating on VRTX. Out of the 3 peers that are also analyzing VRTX, 2 agree with Do's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Hartaj Singh of "Oppenheimer" Initiated at Hold on, Thursday, December 15th, 2016
- Geoff Meacham of "Barclays" Downgraded from Buy to Hold on, Tuesday, November 29th, 2016
This is the rating of the analyst that currently disagrees with Do
- Liisa Bayko of "JMP Securities" Upgraded from Hold to Buy on, Friday, March 17th, 2017
Contributing Sources